AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting

October 27, 2014

Data from Sublingual Sufentanil Development Program Highlights Analgesic Response Compared to IV Morphine in Young vs Elderly Adult Patients

REDWOOD CITY, Calif., Oct. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the American College of Surgeons (ACS 2014) Clinical Congress October 26th to October 30th, 2014 at the Moscone Center in San Francisco, CA. The annual ACS meeting is one of the largest international meetings of surgeons in the world. Pamela Palmer, M.D. Ph.D. will present safety and efficacy data from the phase 3 trials evaluating the Zalviso™ sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain.

Details on the presentation times are as follows:

Wednesday, October 29, 2014 – Poster Session PP20, Poster 51175 – Presentation time 11:30-1:00pm (local time)

Authors: Forrest G. Ringold, MD, Harold S. Minkowitz, MD, Tong-Joo Gan, MD, Keith A. Aqua, MD and Pamela P. Palmer, MD, PhD

Title: **SUFENTANIL SUBLINGUAL TABLET SYSTEM EFFICACY AND FUNCTIONALITY FOLLOWING MAJOR ABDOMINAL SURGERY IN YOUNG AND ELDERLY ADULT PATIENTS**

Wednesday, October 29, 2014 – Poster Session PP20, Poster 51199 – Presentation time 11:30-1:00pm (local time)

Authors: Harold S. Minkowitz, MD, Tong-Joo Gan, MD and Pamela P. Palmer, MD, PhD

Title: **SUFENTANIL SUBLINGUAL TABLET SYSTEM ONSET OF ANALGESIA COMPARED TO IV PATIENT-CONTROLLED ANALGESIA WITH MORPHINE - A PHASE 3 META-ANALYSIS**

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25th, received a Complete Response Letter from the FDA. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, by the end of 2014. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-sublingual-sufentanil-data-presentations-at-the-american-college-of-surgeons-meeting-219197336.html

SOURCE AcelRx Pharmaceuticals, Inc.

Timothy E. Morris, Chief Financial Officer, 650.216.3511, tmorris@acelrx.com; Brian Korb, The Trout Group LLC, 646.378.2923, bkorb@troutgroup.com